He-Wei granules (HWKL) combat cisplatin-induced nephrotoxicity and myelosuppression in rats by inhibiting oxidative stress, inflammatory cytokines and apoptosis. Issue 32 (4th April 2017)
- Record Type:
- Journal Article
- Title:
- He-Wei granules (HWKL) combat cisplatin-induced nephrotoxicity and myelosuppression in rats by inhibiting oxidative stress, inflammatory cytokines and apoptosis. Issue 32 (4th April 2017)
- Main Title:
- He-Wei granules (HWKL) combat cisplatin-induced nephrotoxicity and myelosuppression in rats by inhibiting oxidative stress, inflammatory cytokines and apoptosis
- Authors:
- Song, Zehai
Chang, Hang
Han, Na
Liu, Zhihui
Liu, Ye
Wang, Hui
Shao, Jingxuan
Wang, Zhonglin
Gao, Hao
Yin, Jun - Abstract:
- Abstract : He-Wei granules (HWKL) combat cisplatin-induced nephrotoxicity and myelosuppression in rats by inhibiting oxidative stress, inflammatory cytokines and apoptosis Abstract : As a highly effective antineoplastic chemotherapeutic drug, cisplatin is widely used clinically to treat a variety of human malignancies. However, its clinical use is severely limited by serious side-effects, of which nephrotoxicity and myelosuppression are considered to be the most important because they significantly reduce patient life quality and hinder effective use. In this study, we investigated whether HWKL, a product obtained from modified Ban-xia xie-xin decoction first described 1700 years ago, exhibits protective effects against cisplatin-induced nephrotoxicity and myelosuppression. After intraperitoneal injection of 7 mg kg −1 cisplatin to Wistar rats, nephrotoxicity and myelosuppression were observed. HWKL reduced cisplatin-induced elevations in blood urea nitrogen (BUN) and serum creatinine (Scr) levels, increased water intake and improved renal tubular lesions. Cisplatin-induced increases in tumor necrosis alpha (TNF-α) protein, interleukin-1 beta (IL-1β) protein, cyclooxygenase-2 (COX-2) protein, extracellular signal-regulated kinase (ERK), TNF-α mRNA and IL-1β mRNA were significantly reduced by HWKL and cisplatin-induced oxidative stress was also inhibited by HWKL. Furthermore, HWKL contributed to increase immunological function to combat cisplatin-induced myelosuppression. OurAbstract : He-Wei granules (HWKL) combat cisplatin-induced nephrotoxicity and myelosuppression in rats by inhibiting oxidative stress, inflammatory cytokines and apoptosis Abstract : As a highly effective antineoplastic chemotherapeutic drug, cisplatin is widely used clinically to treat a variety of human malignancies. However, its clinical use is severely limited by serious side-effects, of which nephrotoxicity and myelosuppression are considered to be the most important because they significantly reduce patient life quality and hinder effective use. In this study, we investigated whether HWKL, a product obtained from modified Ban-xia xie-xin decoction first described 1700 years ago, exhibits protective effects against cisplatin-induced nephrotoxicity and myelosuppression. After intraperitoneal injection of 7 mg kg −1 cisplatin to Wistar rats, nephrotoxicity and myelosuppression were observed. HWKL reduced cisplatin-induced elevations in blood urea nitrogen (BUN) and serum creatinine (Scr) levels, increased water intake and improved renal tubular lesions. Cisplatin-induced increases in tumor necrosis alpha (TNF-α) protein, interleukin-1 beta (IL-1β) protein, cyclooxygenase-2 (COX-2) protein, extracellular signal-regulated kinase (ERK), TNF-α mRNA and IL-1β mRNA were significantly reduced by HWKL and cisplatin-induced oxidative stress was also inhibited by HWKL. Furthermore, HWKL contributed to increase immunological function to combat cisplatin-induced myelosuppression. Our findings indicate that HWKL inhibits cisplatin-induced nephrotoxicity and myelosuppression via several mechanisms which operate simultaneously and provide basic evidence to confirm that HWKL could be useful in clinical situations as a protective agent to prevent cisplatin-induced nephrotoxicity and myelosuppression. … (more)
- Is Part Of:
- RSC advances. Volume 7:Issue 32(2017)
- Journal:
- RSC advances
- Issue:
- Volume 7:Issue 32(2017)
- Issue Display:
- Volume 7, Issue 32 (2017)
- Year:
- 2017
- Volume:
- 7
- Issue:
- 32
- Issue Sort Value:
- 2017-0007-0032-0000
- Page Start:
- 19794
- Page End:
- 19807
- Publication Date:
- 2017-04-04
- Subjects:
- Chemistry -- Periodicals
540.5 - Journal URLs:
- http://pubs.rsc.org/en/Journals/JournalIssues/RA ↗
http://www.rsc.org/ ↗ - DOI:
- 10.1039/c7ra02830j ↗
- Languages:
- English
- ISSNs:
- 2046-2069
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8036.750300
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 91.xml